Linked Life Data

20544833

Source:http://linkedlifedata.com/resource/pubmed/id/20544833

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13
pubmed:dateCreated
2010-8-10
pubmed:abstractText
Hypertension reduces endothelial nitric oxide synthase (eNOS) expression and leads to endothelial dysfunction. However, few studies have demonstrated the influences of hypertension on eNOS function in the cerebral cortex. The present study investigates the influences of hypertension on endothelial function in the cerebral cortex and the protective effects of antihypertensive agents against brain ischemia through the preservation of endothelial function. Five- and ten-week-old male Wistar rats and spontaneously hypertensive rats (SHR) were used for experiments. Five-week-old SHR received olmesartan, hydralazine, or vehicle for 5 weeks in drinking water. eNOS activation in the cerebral cortex was evaluated by analyzing levels of total and Ser(1177)-phosphorylated eNOS protein by Western blot. Blood pressure of 10-week-old SHR without treatment was clearly high, and the ratio of phospho-eNOS/total eNOS protein was significantly low. Five-week treatment with olmesartan or hydralazine suppressed the elevation of blood pressure and the reduction of phosphorylated eNOS-Ser(1177) in SHR, and olmesartan was more effective in maintaining phosphorylation of eNOS-Ser(1177) than hydralazine. To assess the contribution of eNOS to maintaining cerebral blood flow (CBF), we monitored CBF by laser-Doppler flowmetry after L-N(5)-(1-iminoethyl)ornithine (L-NIO) infusion. CBF response to L-NIO was preserved in olmesartan-treated SHR but not in hydralazine-treated SHR. Furthermore, infarct volume 48 hr after transient focal brain ischemia in olmesartan-treated SHR was significantly reduced compared with vehicle-treated SHR. These findings indicate that chronic prehypertensive treatment with olmesartan could attenuate brain ischemic injury through the maintenance of endothelial function in the cerebral cortex in SHR.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1097-4547
pubmed:author
pubmed:copyrightInfo
(c) 2010 Wiley-Liss, Inc.
pubmed:issnType
Electronic
pubmed:volume
88
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2889-98
pubmed:meshHeading
pubmed-meshheading:20544833-Angiotensin II Type 1 Receptor Blockers, pubmed-meshheading:20544833-Animals, pubmed-meshheading:20544833-Antihypertensive Agents, pubmed-meshheading:20544833-Brain Infarction, pubmed-meshheading:20544833-Cerebrovascular Circulation, pubmed-meshheading:20544833-Disease Models, Animal, pubmed-meshheading:20544833-Endothelium, pubmed-meshheading:20544833-Gene Expression Regulation, pubmed-meshheading:20544833-Hypoxia-Ischemia, Brain, pubmed-meshheading:20544833-Imidazoles, pubmed-meshheading:20544833-Nitric Oxide Synthase Type III, pubmed-meshheading:20544833-Phosphorylation, pubmed-meshheading:20544833-Rats, pubmed-meshheading:20544833-Rats, Inbred SHR, pubmed-meshheading:20544833-Rats, Wistar, pubmed-meshheading:20544833-Tetrazoles, pubmed-meshheading:20544833-Time Factors
pubmed:year
2010
pubmed:articleTitle
An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats.
pubmed:affiliation
Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan. oyama@medone.med.osaka-u.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't